We have pioneered the development of a cell-engineering platform based on Flow Electroporation® Technology. Originally conceived to meet the stringent demands of cell therapy applications – namely, the ability to safely and reproducibly modify human cells with high efficiency, low cytotoxicity and at the scale required to treat patients – we have expanded the platform and applications to accelerate the development of small molecule drugs, biologics and vaccines, in addition to enhancing cell therapy applications.
Invented at the CBR Institute for Biomedical Research in Boston, Massachusetts, Flow Electroporation Technology was initially intended for the clinical treatment of ischemic disorders by loading an autologous red blood cell suspension with an alternative hemoglobin oxygen modulator. While the Company was founded in 1999 to commercialize this technology, our scientists have since greatly expanded on this capability to load a wide range of biologically active molecules into a variety of cell types to enable many clinical and commercial applications.
In 2000, we developed the MaxCyte GT® Scalable Transfection System for cell therapy development and commercialization. In 2003, we began entering license agreements with developers of human cell therapies to enable the development of novel therapeutic products based on our delivery platform. With the launch of the MaxCyte STX® Scalable Transfection System, the powerful platform was opened to the burgeoning areas of cell-based assays for high-throughput and high-content screening and preclinical protein production, greatly enhancing the speed and productivity in these fields.
Most recently, our delivery platform has been employed in the exciting and growing fields of immuno-oncology and gene editing. In addition, with the announcement of our CARMA™ approach for development of our own therapies to combat multiple diseases, we are advancing a unique application of our proprietary Flow Electroporation Technology.
MaxCyte is evaluating its first autologous CAR drug candidate in mesothelin-expressing solid tumors. This product candidate, MCY-M11, employs repeat infusions of mesothelin-specific human mRNA CAR-transfected into peripheral blood mononuclear cells (PBMCs) to allow for “controlled persistence.” Early non-clinical testing has provided preliminary evidence of the anti-tumor activity of this drug.
In April 2019, MaxCyte announced the launch of the ExPERT™ technology platform. This family of instruments – the ATx, STx and GTx – represents the next generation of the industry’s leading, clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, MaxCyte continues its uncompromising focus on high performance cellular editing, while delivering feature enhancements that will enable customers to use a single unifying technology, from concept to commercialization.